Skip to main content

Table 5 Therapeutic strategies targeting the TGF-β pathway

From: Combination strategies to maximize the benefits of cancer immunotherapy

Therapeutic categories Targets Drugs
Small molecules TGF-βR1 Galunisertib, vactosertib, BMS-986260, LY3200882; PF-06952229
Antibodies Pan-TGF-β Fresolimumab, SAR439459, NIS793
Glycoprotein-A repetitions predominant (GARP)- TGF-β1 ABBV-151
TGF-β1 and TGF-β2 XPA-42-089
Bi-specific antibodies TGF-βRII and PD-L1 Binstrafusp alfa
TGF-βRII and CTLA4 a-CTLA4-TGFβRIIecd
Antisense TGF-β2 Trabedersen
Modified ACT Dominant-negative TGF-βRII